Integrating GLP-1 Management into the Medicare Annual Wellness Visit (AWV)

Editor's Note: The Medicare GLP-1 Bridge is an evolving federal demonstration, currently authorized through December 31, 2027. The Part D portion of the successor BALANCE Model has been delayed and no replacement has been finalized. This information is subject to change based on upcoming CMS guidance and federal rulemaking.

Key Takeaways:

• The Bridge is a Section 402 demonstration operating outside the Part D benefit, authorized only through December 31, 2027, with no successor pathway finalized.
• Eligibility is defined by body mass index and comorbidity as they stood at the time therapy was initiated, and includes no assessment of muscle mass, physical function, or nutritional status.
• The three covered products are not pharmacologically interchangeable, and one carries drug-interaction considerations the others do not.

Obesity management for the Medicare population changed in July 2026. The Medicare GLP-1 Bridge gives eligible beneficiaries time-limited access to three products for weight management: two glucagon-like peptide-1 (GLP-1) receptor agonists and one dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.¹ But eligibility answers a payer question rather than a clinical one, and the Annual Wellness Visit (AWV) is where both questions land in the same appointment.

What eligibility does not ask

Qualification rests on body mass index and comorbidity as they stood when therapy was initiated: a BMI of 35 or above alone; 30 or above with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above; or 27 or above with pre-diabetes, prior myocardial infarction, stroke, or symptomatic peripheral artery disease.¹ Type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction–associated steatohepatitis are disqualifying, because those are already Part D–covered indications.¹

Nowhere in that framework is muscle mass, physical function, or nutritional status. Two further facts belong in the same conversation. The demonstration is authorized only through December 31, 2027, with the successor model's Part D portion delayed and no replacement finalized.² And because the Bridge operates outside the Part D benefit, the $50 copay does not apply to the deductible, does not accrue toward true out-of-pocket costs, and is not reduced by the low-income subsidy.³ For a dual-eligible patient, it is more expensive at the counter, not less.

What the visit already captures

The AWV's required elements do more of this work than clinicians typically use. The first AWV requires height, weight, BMI or waist circumference, and blood pressure. Subsequent visits require weight or waist circumference and blood pressure, and do not list BMI at all.⁴ Since BMI is the number the coverage pathway turns on, calculating it at every visit rather than relying on the required list is a small change with real downstream consequences.

The visit also already requires a review of functional ability and safety, including activities of daily living and fall risk.⁴ Sharpening that review for a patient who may start therapy is not an addition to the visit. One boundary is worth naming: prescribing and managing pharmacotherapy is not part of the AWV benefit, and where that work happens at the same visit it is a separately identifiable evaluation and management service reported with modifier 25.⁴

Muscle mass and function

Incretin-based weight loss is not selective for fat. All three product labels state that these agents reduce weight with greater fat mass loss than lean mass loss.^9,10,11 None quantifies the lean-mass share, and published estimates vary widely across studies.⁶

The evidence in older adults points in more than one direction. A 24-month cohort of adults aged 65 and older with type 2 diabetes receiving semaglutide found significant declines in appendicular skeletal muscle mass index, handgrip strength, and gait speed versus matched controls; that is a population the Bridge disqualifies, so applying it here is an extrapolation.⁷ A post hoc analysis of a dual GIP and GLP-1 receptor agonist found no disproportionate lean-mass loss in participants aged 65 and older.⁶ Neither has been replicated above age 75, where the trials are nearly empty: across the three Bridge products, patients that age accounted for 2 percent or less of those treated.^9,10,11

Three steps fit inside the visit:

• Screen, then measure. SARC-F is a reasonable screen.⁸ Handgrip below 16 kg in women or 27 kg in men, a five-times-sit-to-stand above 15 seconds, gait speed of 0.8 m/s or less, or a Short Physical Performance Battery score of 8 or less each identify reduced functional reserve.⁵
• Pair therapy with resistance exercise and a specified protein target: 1.0 to 1.2 g/kg per day, at least 25 g at each of three main meals, and not above 1.2 g/kg in impaired renal function.⁵
• Watch tolerability above 75, where gastrointestinal effects may amplify the anorexia of ageing.⁵ The American College of Physicians advises counseling patients on unintended effects of weight loss, including adverse changes in body composition, particularly in older adults.¹²

Adjusting the rest of the regimen

Documenting medications and supplements is a required AWV element. A full medication review is not mandated, but starting incretin therapy is a reasonable trigger for one.⁴ All three labels note that delayed gastric emptying may affect absorption of oral medications, and two advise closer monitoring for drugs with a narrow therapeutic index, the tirzepatide label naming warfarin.^9,10,11 The small-molecule oral agent adds a consideration the peptides do not have: it is a CYP3A4 substrate, so its labeling caps the dose with strong inhibitors, advises avoiding strong inducers, and limits concurrent simvastatin to 20 mg daily.¹¹

As weight comes down, antihypertensive and glucose-lowering regimens need planned dose reduction rather than reactive adjustment. All three labels report more hypotension in patients on concomitant antihypertensive therapy, and all three advise considering a reduction in insulin or an insulin secretagogue at initiation.^9,10,11

What the visit can accomplish

None of this requires a new workflow. It requires treating coverage eligibility and clinical appropriateness as two separate questions, because only one of them appears on the prior authorization form.